MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 05.03.2026
EyePoint Pharmaceuticals Betriebsaufwand 2011-2026 | EYPT
Betriebsaufwand Jährlich EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 275 M | 189 M | 121 M | 141 M | 92.2 M | 65.9 M | 65.5 M | 29.2 M | 26.1 M | 23.4 M | 20.1 M | 17 M | 14.2 M | 13.9 M | 15 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 275 M | 13.9 M | 73.9 M |
Betriebsaufwand Vierteljährlich EyePoint Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 M | 67.6 M | 73.3 M | - | 43.3 M | 44 M | 45 M | - | 29.6 M | 31.9 M | 29.2 M | - | 28.4 M | 30.8 M | 27.6 M | - | 24.4 M | 20 M | 18.3 M | - | 17.7 M | 15.3 M | 18.9 M | - | 16.6 M | 17.4 M | 16.7 M | - | 14 M | 10.5 M | 14 M | 6.74 M | 6.39 M | 13.1 M | 6.39 M | 6.06 M | 7.46 M | 6.06 M | 7.46 M | 5.76 M | 5.45 M | 5.76 M | 5.45 M | 4.64 M | 4.52 M | 4.64 M | 4.52 M | 4.13 M | 4.32 M | 4.13 M | 4.32 M | 3.23 M | 3.14 M | 3.23 M | 3.14 M | 18.3 M | 4.19 M | 18.3 M | 4.19 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 73.3 M | 3.14 M | 17.2 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 0.81 | -3.11 % | $ 37 M |  Israel |
 |
Exelixis
EXEL
|
598 M | $ 46.21 | -5.11 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
125 M | $ 2.43 | -4.71 % | $ 67.8 M | USA |
 |
Heron Therapeutics
HRTX
|
281 M | $ 1.24 | -5.73 % | $ 207 M | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 2.86 | 14.2 % | $ 192 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
752 M | $ 75.53 | -1.72 % | $ 12.1 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 92.4 | -3.0 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Kymera Therapeutics
KYMR
|
389 M | $ 85.56 | -0.81 % | $ 7.23 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
115 M | $ 212.11 | -8.79 % | $ 3.88 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.02 | 2.51 % | $ 3.65 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
543 M | $ 100.27 | -8.92 % | $ 5.03 B | USA |
 |
MannKind Corporation
MNKD
|
88 M | $ 3.59 | 0.7 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.65 | 8.96 % | $ 6.01 M | Israel |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Genprex
GNPX
|
18 M | $ 0.88 | -1.48 % | $ 821 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
24.4 M | $ 0.65 | -4.03 % | $ 3.56 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
43.4 M | $ 43.46 | 3.82 % | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.33 | -11.75 % | $ 2.71 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
67.9 M | $ 27.16 | -2.62 % | $ 16.8 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |